Impact on outcomes after listing and transplantation, of a strategy to accept ABO blood group-incompatible donor hearts for neonates and infants  by West, Lori J. et al.
West et al Cardiothoracic TransplantationImpact on outcomes after listing and transplantation, of a
strategy to accept ABO blood group-incompatible donor
hearts for neonates and infants
Lori J. West, MD, DPhil, Tara Karamlou, MD, Anne I. Dipchand, MD, Stacey M. Pollock-BarZiv, PhD, John G. Coles, MD,
and Brian W. McCrindle, MD, MPH
TXFrom the Division of Cardiology, Depart-
ment of Pediatrics, The Hospital for Sick
Children, University of Toronto, Toronto,
Ontario, Canada.
Presented, in part, at the American Heart
Association Annual Scientific Sessions, Or-
lando, Fla, November 2003.
Received for publication July 19, 2005; re-
visions received Sept 6, 2005; accepted for
publication Sept 15, 2005.
Address for reprints: Brian W. McCrindle,
MD, The Hospital for Sick Children, 555
University Ave, Toronto, Ontario, Canada
M5G 1X8 (E-mail: brian.mccrindle@
sickkids.ca).
J Thorac Cardiovasc Surg 2006;131:455-61
0022-5223/$32.00
Copyright © 2006 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.09.048Background: Recent data suggest that ABO blood group-incompatible donor hearts
are immunologically well tolerated in infants undergoing transplantation.
Methods: Competing-risks methodology was used to assess outcomes after listing
and the impact of a strategy to accept heart grafts from any blood group donor for
infants less than 18 months of age.
Results: From 1992 to 2002, there were 91 listing episodes in 84 patients (including
20 fetuses; 50% were male and 63% had congenital heart disease). Beginning in
1995, a strategy to accept ABO-incompatible organs was adopted. Competing-risks
analysis showed that after 20 months 60% underwent transplantation, 18% died, and
less than 1% were still listed; the remaining 21% were de-listed because of a change
of surgical strategy (9%), improved clinical condition (8%), and deterioration to
ineligibility (4%). Risk factors for transplantation included only a strategy to accept
ABO-incompatible organs (P .001). Risk factors for death included failure to
accept ABO-incompatible organs (P.002) and Canadian listing status 3 (P.085)
or 4 (P.001). Multivariable parametric models were used to create competing risk
predictions for outcomes specific to status and ABO-incompatible strategy. Higher
status resulted in greater mortality regardless of strategy, although for any status,
more patients underwent transplantation and fewer died using a strategy to accept
ABO-incompatible organs. Parametric modeling of time-related freedom from death
or retransplantation demonstrated no significant difference at 4 years posttransplan-
tation (P .78) for ABO-incompatible (74%) versus ABO-compatible transplants
(72%).
Conclusions: A strategy to accept ABO-incompatible donor hearts for infant trans-
plantation significantly improves the likelihood of transplantation and reduces
waiting list mortality while not adversely altering outcomes after transplantation.
Since the early days of organ transplantation, ABO blood group compatibilitybetween donors and recipients has been understood to be mandatory becauseof the high risk of “hyperacute” rejection.1-3 This process occurs when
preexisting recipient “natural” antibodies (isoagglutinins) directed against donor A
and/or B blood groups bind their cognate antigens on donor organ endothelium. A
rapidly progressive cascade is initiated with complement activation and recruitment
of other inflammatory mediators, leading to irreversible and widespread thrombosis
of graft vasculature. Because of the chronic shortage of donor organs, attempts have
been made to bridge the blood group barrier, with some success in kidney and liver
transplantation.3-10 These attempts have required aggressive strategies to remove
antidonor antibody, including splenectomy, plasmapheresis, and immunoadsorption,
but antibody often reaccumulates because of B-cell memory combined with antigen
persistence.
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TXHeart transplantation across ABO incompatibility is
never undertaken intentionally in adults because of the high
lethality rate of the few reported accidental cases.11 We
previously reported that the requirement for ABO compat-
ibility in heart transplantation seems to be unnecessary for
young infants because of their natural delay in development
of humoral immunity to T-independent antigens, including
isoagglutinin production.12 In the present study we sought
to determine the impact on outcomes, after listing and
transplantation, of adopting a strategy to accept ABO-in-
compatible (ABO-I) donor hearts for infants.
Methods
Patient Characteristics
From computerized databases, all infants less than 18 months of
age at listing from 1992 to 2002 were identified. All patients were
cared for and underwent transplantation at the Hospital for Sick
Children. Data regarding patient characteristics and outcomes were
collected. Historical patients from the same institution were com-
pared with patients who were listed with an ABO-I strategy and
who underwent an ABO-I transplantation in an unmatched
comparison.
We identified 91 listing episodes in 84 patients. Fifty percent of
the patients were male, and 63% had congenital heart disease, with
48% having hypoplastic left heart syndrome. ABO blood group
was group O in 41 patients (49%), group A in 33 patients (39%),
group B in 8 patients (10%), and group AB in 2 patients (4%).
Twenty patients were initially listed in utero. Of the remaining
episodes, the median age at listing was 2.7 months, ranging from
birth to 18 months. Seven listing episodes occurred while the
patient was on extracorporeal membrane oxygenation. The status
at listing (Canadian status system) was 3.5 to 4 (most urgent) in
41%, 3 in 44%, and 1 (least urgent) or 2 in 15% (Table 1).
Beginning in 1995 a strategy to accept ABO-I donor hearts was
adopted, meaning that all infants less than 18 months of age were
listed for any donor blood group rather than indicated for a specific
donor blood group, as had been our previous strategy. All infants
less than 18 months of age were assessed for appropriateness for
listing for ABO-I heart transplantation. The decision to list a
patient for a potential donor of any blood group was based on the
(1) absence or low level of preformed isohemagglutinins and (2)
parental consent. No parents refused to accept an ABO-I graft
during the study period. Patients of any status level were eligible,
and therefore patients were not excluded from this listing strategy
if they were “too well.” Organs were allocated by the established
method in Canada, taking into consideration listing status and
geographic location. During the course of the study, 20 donor
organs were procured from the United States. There was no sep-
arate allocation algorithm for patients listed for ABO-I transplan-
tation (ie, the organ was not offered to an ABO-I recipient only if
Abbreviations and Acronyms
ABO-I ABO incompatiblethere was no compatible recipient). Organs were accepted on the
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both donor and recipient factors. Blood group was not factored into
the decision making (ie, a patient on the ABO-I list received the
first good-quality organ, and organs were not declined on the basis
of blood group incompatibility even if the recipient was stable).
Overall, 76% of listing episodes (69 listing episodes in 65
patients) included in the study were made with an ABO-I strategy.
Sixteen patients with an ABO-I listing eventually underwent trans-
plantation with ABO-I hearts. Thus, the majority of patients (75%)
listed with the ABO-I strategy still received ABO-compatible
organs.
Statistical Analysis
Data are described as frequencies, medians with ranges, and means
with standard deviations as appropriate. To determine the impact
of the ABO-I blood group strategy on outcomes after listing, the
following mutually exclusive time-related states were defined:
death, achievement of transplantation, removal from the list, and
ongoing survival without transition to another state. In addition,
the state of having been removed from the list was further defined
according to the following reasons: the patient’s clinical status
improved such that transplantation was no longer necessary, the
patient’s clinical status deteriorated such that he or she was no
longer considered a candidate for transplantation (eg, multiorgan
failure), or the patient had an alternative procedure (eg, Norwood
Stage I operation for hypoplastic left heart syndrome). The rates of
transition from the initial state to each competing state were
determined, and these were synthesized in a competing-risks anal-
ysis to give the proportion of listed patients achieving each state at
any given time after listing.13 Risk-unadjusted nonparametric es-
timates of time-related freedom from each state were plotted as
Kaplan-Meier estimates. Calculation of parametric estimates of
time-related freedom from each state was achieved by modeling
the hazard function and determining the characteristic equation for
each phase of risk.14 Factors associated with each state, especially
use of the ABO-I blood group strategy, were sought in multivari-
able hazard analysis in the totally parametric domain. Factors
associated with 5 or fewer events were not considered to minimize
the risk of model overdetermination. Bootstrap bagging was used
to guide final factor selection as previously described.15 The mul-
tivariable models were then solved in a competing-risks analysis to
demonstrate the magnitude of effect of significant factors on the
proportion of patients transitioning to all states. In addition, factors
associated with time-related outcomes after transplantation were
also sought. Because events were infrequent, the major time-
related outcomes of death and retransplantation were combined,
and an analysis similar to that previously described was performed
without the competing-risks component.
Results
Events After Listing
Mortality. Time-related death after listing occurred for
16 patients (Figure 1, A). There was a gradual early hazard
or risk phase, with an ongoing risk of death up to 20 months
after listing. Incremental risk factors for death included
status 3 or 4 (more “ill”) at time of listing (P .001,
bootstrap reliability 91%) and failure to use the ABO-I
uary 2006
ICU,
West et al Cardiothoracic Transplantation
TXlisting strategy (P .002, bootstrap reliability 69%). No
other factors were significantly associated with death with-
out transplantation, including date and age at listing.
Transplantation. Figure 1, B shows the time-related
freedom from transplantation, with 54 listing episodes re-
sulting in transplantation. Sixteen patients received ABO-I
grafts, and 38 patients received ABO-compatible grafts.
ABO-I recipients were similar to those receiving ABO-I
grafts (Table 2). There was a single prolonged early hazard
or risk phase. The only significant factor predicting trans-
plantation was the use of the ABO-I listing strategy
(P .001, bootstrap reliability 86%).
De-listing. Removal from the list occurred in 20 pa-
tients. Reasons for removal included (1) clinical deteriora-
tion to ineligibility for transplantation in 4 patients; (2)
clinical improvement in 8 patients; and (3) performance of
an alternative procedure in 8 patients. Risk factors were not
Figure 1. Time-related freedom from outcomes after
while listed. B, Time-related freedom from transplant
(circles with bars). Parametric model of the hazard f
TABLE 1. Canadian status at listing compared with United
Canadian status (no separate pediatric listing policy like UNOS)
1: Waiting at home
2: Hospitalized with complication of heart disease
3: Ward care  VAD or inotropes
3.5: ICU care  PA catheter  high-dose/multiple IV inotropes
4: ICU care  mechanical ventilatory or circulatory support
UNOS, United Network for Organ Sharing; VAD, venous access device;lines). Number of patients at risk (numbers at top of graph
The Journal of Thoracisought for these events because of the small number of
patients achieving these less frequent events.
Competing-risks analysis. The majority of events oc-
curred within the first 3 months after listing. The competing-
risks depiction of all 6 mutually exclusive end states occur-
ring after listing is shown in Figure 2. Competing-risks
analysis predicted that at 20 months after listing, 60% of the
patients had undergone transplantation, 18% had died while
listed, and 21% had been de-listed. Of those who were
de-listed, an alternative procedure was performed in 9%,
8% were removed from the list because they improved, and
4% were removed because of clinical deterioration preclud-
ing transplantation.
Outcome predictions were generated by solving the mul-
tivariable competing-risk equations for the 2 significant
incremental risk factors, including status at listing and use
of the ABO-I strategy. Use of the ABO-I strategy resulted in
g for transplant. A, Time-related freedom from death
after listing. Nonparametric Kaplan-Meier estimates
on (solid line) with 70% confidence interval (dashed
twork for Organ Sharing
UNOS pediatric patient status
2: Patient not meeting criteria for status 1A or 1B
1B: One of the following:
Low-dose single inotrope, 6 months old but not
meeting 1A criteria, growth failure (pediatric)
1A: One of the following:
Ventilator, mechanical assist device, balloon
pump, high-dose or multiple inotropes, patient
 6 months old with congenital or acquired
heart disease exhibiting reactive pulmonary
hypertension at  50% of systemic level; life
expectancy of  14 days without a heart
transplant
intensive care unit; PA, pulmonary artery.listin
ation
unctiNe).
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TXimportant decreases in the proportion of patients who died,
regardless of the patient’s status at listing (Figure 3, A), and
as expected, lower status at listing (less “ill”) was also
associated with lower mortality. Similarly, use of the ABO-I
strategy also resulted in an important increase in the pro-
portion of patients achieving transplantation, regardless of
their status at listing, with patients at lower status more
likely to achieve transplantation (Figure 3, B).
Figure 4, A, shows the time-related freedom from either
death (n  13) or retransplantation (n  2) after transplan-
tation. There was a steep early hazard phase followed by an
ongoing low constant phase of risk. Parametric estimates of
freedom from this composite outcome were 73% at 1 year,
Figure 2. Competing-risks depiction of events after listing for
transplant. All patients begin alive and thereafter migrate to 1 of
6 mutually exclusive end states (death, transplantation, de-listing
secondary to clinical deterioration, de-listing secondary to im-
proved clinical condition, de-listing secondary to a change in
surgical procedure, and remaining alive without transplantation)
at a time-dependent rate defined by the underlying hazard func-
tions. At any point in time, the sum of the proportion of children
in each state is 100%. For example, the estimated prevalences at
20 months after listing are as follows: transplantation (60%),
death without transplantation (18%), de-listed (21%), and alive
without transplantation (<1%). Parametric point estimates (solid
TABLE 2. Characteristics of patients who underwent trans
Variable
ABO-I recipie
(n  16)
Male 7 (43%)
Diagnosis
HLHS 10 (63%)
Other CHD 12 (75%)
Pretransplant ECMO 2 (12%)
Median age at listing, mo 21 d (in utero-
Median age at transplant, mo 2 (birth–15
ABO-I, ABO-incompatible; HLHS, hypoplastic left heart syndrome; ECMOlines).
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Risk factors were sought for this time-related outcome, and
none were significant, specifically that of receiving an
ABO-I organ (Figure 4, B).
Discussion
Long-term survival for patients undergoing heart transplan-
tation in early infancy has improved, especially when con-
sidering conditional survival beyond 12 months posttrans-
plant.16,17 This may be partly because of the ease of
manipulating the infant immune response to the trans-
planted organ, an immunologic advantage that seems most
pronounced in neonatal recipients.18 However, wider avail-
ability of this therapy for infants with otherwise lethal
cardiac malformations and cardiomyopathies has been se-
verely limited by the critical shortage of donor organs of
both compatible blood group and appropriate size.
The perceived requirement for ABO compatibility has
been demonstrated to be particularly detrimental for infants
of blood group O awaiting transplantation, who face dis-
proportionate competition for blood group O donors whose
organs are compatible with all 4 recipient blood groups.19
Moreover, a paucity of data and lack of consensus guide-
lines for brain death determination in the very young have
further exacerbated the scarcity of potential organ donors
for the smallest recipients.20 Thus, infants have had rela-
tively higher mortality rates while awaiting transplantation
than older (and larger) patients.19
The stringent requirement for ABO compatibility in organ
transplantation evolved for children by extrapolation from ex-
perience with adult patients, rather than as a primary consid-
eration based on appropriate developmental parameters for
pediatrics. The rationale for our initial cohort of ABO-I trans-
plants in infants was based on well-established immunologic
milestones of childhood coupled with a compelling clinical
need to expand the potential pool of organ donors, with the
added knowledge that available organs were being wasted
because of lack of ABO-compatible recipients. Our initial
experience demonstrated that accepting ABO-I donor organs
tation (N  54)
ABO-compatible recipients
(n  38) P
17 (45%) .94
13 (34%) .06
25 (66%) .50
2 (5%) .26
40 d (in utero-16) .25
3 (birth–30) .24
racorporeal membrane oxygenation; CHD, congenital heart disease.plan
nts
12)
mo)for infant patients during the normal developmental lag in
uary 2006
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TXhumoral immunity was feasible and safe, in the short term at
least, as a partial solution for the critical organ donor shortage.
In the present study, we examined whether our assessment of
the risks and benefits of crossing the ABO barrier was justified
by examining whether adopting a strategy to accept ABO-I
Figure 3. Multivariable competing risks predicting ou
Multivariable competing risks predicting the proportion
status at listing. This graph represents specific solutio
without transplantation using specific values for the p
vs ABO-compatible.) The use of an ABO-I strategy (dash
dying without transplantation for all status groups com
lines). B, Multivariable competing risks predicting the
ABO blood group strategy and status at listing. Si
multivariable competing-risks equation for the achieve
status (1 and 2, 3, or 4) and the ABO strategy (ABO-I v
lines) results in a greater predicted proportion of pat
compared with the use of an ABO-compatible strategy
Figure 4. Time-related freedom from outcomes after
retransplantation after transplantation. Nonparametric
model of the hazard function (solid line) with 70% con
(numbers at top of graph). B, Time-related freedom fromline) versus prediction for patients receiving an ABO-compa
The Journal of Thoracidonor hearts resulted in better outcomes for infants listed for
transplantation.
The only 2 factors we found to be significantly associ-
ated with mortality while waiting were higher status (more
“ill”), reflecting their more urgent need for timely organ
es solved for ABO strategy and status at listing. A,
g while listed solved for ABO blood group strategy and
o the multivariable competing risk equation for death
t status (1 and 2, 3, or 4) and the ABO strategy (ABO-I
nes) results in a lower predicted proportion of patients
ed with the use of an ABO-compatible strategy (solid
rtion achieving transplantation after listing solved for
ly, this graph represents specific solutions to the
of transplantation using specific values for the patient
O-compatible.) The use of an ABO-I strategy (dashed
who underwent transplantation for all status groups
id lines).
splantation. A, Time-related freedom from death or
lan-Meier estimates (circles with bars). Parametric
ce interval (dashed lines). Number of patients at risk
th or retransplantation after transplantation. Predictedtcom
dyin
ns t
atien
ed li
par
propo
milar
ment
s AB
ients
(soltran
Kap
fiden
dea
by ABO-compatible versus ABO-I transplantation. Prediction for patients receiving an ABO-I donor heart (dashed
tible donor heart (solid line). Re-Tx, Retransplantation.
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reflecting the limited donor pool for infants. The only factor
found to be significantly associated with achieving trans-
plantation after listing was use of the ABO-I listing strategy.
Multivariable competing-risks analysis allowed us to deter-
mine the impact of identified risk factors on the rate of
transition to each of the 6 defined end states and the pro-
portion of patients achieving each state. We found that
adoption of the ABO-I listing strategy resulted in an impor-
tant decrease in the number of patients who died without
transplantation and a corresponding increase in those who
underwent transplantation regardless of patient status at
listing. Thus, considerable positive clinical impact occurs
with the adoption of a prospective ABO-I listing strategy,
independent of other factors.
Our data also show that use of an ABO-I strategy did not
adversely affect outcomes after transplantation. Specifically,
we determined that the risk of either mortality or retransplan-
tation after primary transplantation was not increased by re-
ceiving an ABO-I heart graft. Two particular posttransplant
problems reported to be associated with antidonor antibodies in
adult transplant recipients, acute humoral rejection and trans-
plant vasculopathy, were not specifically examined in this
study. However, our data21 demonstrating that infant recipients
of ABO-compatible heart grafts spontaneously develop spe-
cific B-cell tolerance to donor blood group antigens over time
suggests that their risk of developing these clinical problems is
no greater than for ABO-compatible infant recipients. More-
over, the identical rate of freedom from death and retransplan-
tation between ABO-I and ABO-compatible recipients further
confirms that humoral rejection and vasculopathy are likely not
of clinically significant difference.
Using an ABO-I strategy for heart transplantation obviously
will not generate an increased number of organ donors. How-
ever, allocation of heart grafts for infant transplantation unre-
stricted by the need for ABO compatibility between donor and
recipient could result in redistribution of those rarely available
organs of suitable size for infants such that more infants would
benefit from transplantation, especially in conjunction with
other strategies such as marginal donors, non–heart-beating
donors, and geographic matching. Wastage of unplaced donor
hearts from the rarer B and AB blood group donors, estimated
to be up to 60% of those available,22 could be minimized.
Furthermore, donor hearts that might require transportation to
geographically distant centers to be used for ABO-compatible
recipients could be redirected to closer centers. This redistri-
bution would result in decreased graft ischemia times with a
concomitant reduction in the associated detrimental effect on
posttransplant outcomes.23,24
Conclusion
The adoption of a strategy to accept ABO-I donor hearts for
infant transplantation significantly improves the chances of
460 The Journal of Thoracic and Cardiovascular Surgery ● Febrtransplantation and reduces death while on the waiting list.
In addition, the risks of death or retransplantation after
primary transplantation are not adversely affected by receiv-
ing an ABO-I heart in this age group. These data continue
to support our position that there is no scientific rationale to
require ABO compatibility for infant heart transplantation,
and that young recipients with absent or low isohemagglu-
tinin titers should be offered ABO-I transplantation regard-
less of clinical status.
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